Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
In TRIUMPH-2, discontinuation due to adverse events ranged from 3.8% to 11.6% across retatrutide dose groups compared with 4.9% for placebo
PIONEER 2 included patients only receiving metformin, while PIONEER 3 included patients receiving metformin with or without sulfonylurea and PIONEER 4 included patients receiving metformin with or without an SGLT-2 inhibitor
Clinical and biochemical features of patients comprised in K1, K2, and K3 clusters
Research by Kwon and Park involving 32 white rabbits divided into four groups explored the extent of cartilage degeneration following exposure to a placebo, AOD 9604 alone, hyaluronic acid alone, or a combination of AOD 9604 and hyaluronic acid over a period of 4 to 7 weeks
In the phase 2 type 2 diabetes trial, the highest Retatrutide arms lowered A1C by around 1.9% to 2.0% by week 24, alongside body weight reductions near 16% to 17% by week 36
US$ 24.92
US$ 25.53
US$ 20.51
US$ 20.57
US$ 21.59
/https%3A%2F%2Fopengraph.b-cdn.net%2Fproduction%2Fimages%2F2ed46913-f157-43c3-9418-19fea49af16c.png%3Ftoken%3DUl4O1QAtXTaMUjOfpBooUL-C8jajM-YwYFPrjCtr6ms%26height%3D1080%26width%3D1080%26expires%3D33315971423/og.png)
